This open-label, single-arm study evaluates the safety and preliminary efficacy of LC-K76 combined with Tislelizumab and ADT in 10 patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) who progressed on prior therapies. Participants will receive oral LC-K76 and intravenous Tislelizumab for a 24-week treatment period.
Male, aged 18 to 85 years.
Histologically confirmed prostate adenocarcinoma, without small cell carcinoma components.
Metastatic Castration-Resistant Prostate Cancer (mCRPC) with disease progression after at least one novel endocrine therapy (e.g., abiraterone or enzalutamide) and/or docetaxel chemotherapy.
Evidence of bone metastasis on PSMA-PET-CT or bone scan (ECT).
Lack of pathological evidence for prostate cancer.
Other primary malignant tumors active or requiring treatment within the past 3 years.
Has visceral metastases.
Poorly controlled diabetes after continuous insulin therapy.